Akebia Therapeutics (AKBA) Tops Q1 EPS by 8c
Tweet
Share
E-mailGet Alerts AKBA Hot Sheet
Join SI Premium – FREE
Akebia Therapeutics (NASDAQ: AKBA) reported Q1 EPS of $0.03, $0.08 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $57.34 million versus the consensus estimate of $44.38 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ADP Employment Change (Aug) 38K vs 47K Expected
- FuelCell Energy (FCEL) Misses Q3 EPS by 24c
- UBS Reiterates Neutral Rating on Fiserv (FISV)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
